Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Lignende værker

• Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
  af: Yip, Terry Cheuk-Fung, et al.
  Udgivet: (2020)
• Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
  af: Hui, Vicki Wing-Ki, et al.
  Udgivet: (2021)
• Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy
  af: Wong, Grace Lai-Hung, et al.
  Udgivet: (2013)
• Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B
  af: Liang, Lilian Yan, et al.
  Udgivet: (2021)
• Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
  af: Jeon, Mi Young, et al.
  Udgivet: (2021)